Download PDF
Thromb Haemost 1979; 41(02): 365-383
DOI: 10.1055/s-0038-1646786
Original Articles
Schattauer GmbH Stuttgart

Studies on the Fibrinolytic System in Human Plasma: Quantitative Determination of Plasminogen Activators and Proactivators

C Kluft
The Gaubius Institute, Health Research Organization TNO, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 06 February 1978

Accepted 07 April 1978

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Effects due to plasma plasminogen activators and proactivators are usually studied in assay systems where inhibitors influence the activity and where the degree of activation of proactivators is unknown. Quantitative information on activator and proactivator levels in plasma is therefore not available

Studies on the precipitating and activating properties of dextran sulphate in euglobulin fractionation presented in this paper resulted in the preparation of a fraction in which there was optimal recovery and optimal activation of a number of plasminogen activators and proactivators from human plasma. The quantitative assay of these activators on plasminogen-rich fibrin plates required the addition of flufenamate to eliminate inhibitors. The response on the fibrin plates (lysed zones) could be coverted to arbitrary blood activator units (BAU). Consequently, a new activator assay which enables one to quantitatively determine the plasma level of plasminogen activators and proactivators together is introduced.

Two different contributions could be distinguished: an activity originating from extrinsic activator and one originating from intrinsic proactivators. The former could be assayed separately by means of its resistance to inhibition by Cl-inactivator. Considering the relative concentrations of extrinsic and intrinsic activators, an impression of the pattern of activator content in plasma was gained. In morning plasma with baseline levels of fibrinolysis, the amount of extrinsic activator was negligible as compared to the level of potentially active intrinsic activators. Consequently, the new assay nearly exclusively determines the level of intrinsic activators in morning plasma. A pilot study gave a fairly stable level of 100 ± 15 BAU/ml (n = 50). When fibrinolysis was stimulated by venous occlusion (15 min), the amount of extrinsic activator was greatly increased, reaching a total activator level of 249 ± 27 BAU/ml (n = 7).

 

  • References

  • 1 Anderson AJ, Lack CH. 1964; The formation, composition and fibrinolytic potential of chondromucoprotein-fibrinogen and chondromucoprotein-lipoprotein complexes in human euglobulin fractions. Clinical Science 26: 97
    PubMedGoogle Scholar
  • 2 Anderson AJ. 1965; Effect of anionic polyelectrolytes on the formation and composition of plasma euglobulins. Nature 207: 408
    CrossrefPubMedGoogle Scholar
  • 3 Astrup T, Kok P. 1970. Assay and preparation of a tissue plasminogen activator. In: Colowick SP, Kaplan MO. (eds.) Methods in Enzymology. Academic Press; London: p 821
    Google Scholar
  • 4 Astrup T, Rosa AT. 1974; A plasminogen proactivator-activator system in human blood effective in absence of Hageman factor. Thrombosis Research 4: 609
    CrossrefPubMedGoogle Scholar
  • 5 Brakman P. 1967 Fibrinolysis, a standardized fibrin plate method and a fibrinolytic assay of plasminogen. Thesis, Scheltema & Holkema, Amsterdam.
    PubMedGoogle Scholar
  • 6 Brakman P, Albrechtsen OK, ASTRUP T. 1966; A comparative study of coagulation and fibrinolysis in blood from normal men and women. British Journal of Haematology 12: 74
    CrossrefPubMedGoogle Scholar
  • 7 Brakman P, Astrup T. 1964; Fibrinolytic activity in human blood assayed in a peptone-like system. Sangre 9: 46
    PubMedGoogle Scholar
  • 8 Deutsch DG, Mertz ET. 1970; Plasminogen purification from human plasma by affinity chromatography. Science 170: 1095
    CrossrefPubMedGoogle Scholar
  • 9 Forbes CD, Pensky J, Ratnoff OD. 1970; Inhibition of activated Hageman factor and activated thromboplastin antecedent by purified Cl-inactivator. The Journal of Laboratory and Clinical Medicine 76: 809
    PubMedGoogle Scholar
  • 10 Haupt H, Heimburger N, Kranz T, Schwick HG. 1970; Ein Beitrag zur Isolierung und Charakterisierung des Cl-Inaktivators aus Human Plasma. European Journal of Biochemistry 17: 254
    CrossrefPubMedGoogle Scholar
  • 11 Haverkate F, Brakman P. 1975. Fibrin plate assay. In: Davidson JF, Samama MM, Desnoyers PC. (eds.) Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 1.1. Raven Press; New York: p 151
    Google Scholar
  • 12 Haverkate F, Traas DW. 1974; Dose-response curves in the fibrin plate assay. Fibrinolytic activity of proteases Thrombosis et Diathesis Haemorrhagica (Stuttgart) 32: 356
    PubMedGoogle Scholar
  • 13 Iatridis SG, Ferguson JH. 1962; Active Hageman factor: A plasma lysokinase of the human fibrinolytic system. Journal of Clinical Investigation 41: 1277
    CrossrefPubMedGoogle Scholar
  • 14 Kaplan AP, Austen KF. 1972; The fibrinolytic pathway of human plasma. Isolation and characterization of plasminogen proactivator Journal of Experimental Medicine 136: 1378
    CrossrefPubMedGoogle Scholar
  • 15 Von Kaulla KN. 1970. On the in vitro mechanism of synthetic fibrinolytic agents. In: SCHOR JM. (Ed.) Chemical Control of Fibrinolysis-Thrombolysis. Wiley Interscience. New York: p 1
    Google Scholar
  • 16 Kluft C. 1975. Cl-inactivator as a determining factor in contact activation of fibrinolysis. 5th Congress International Society on Thrombosis and Haemostasis Paris: Abstract nr 333
    Google Scholar
  • 17 Kluft C. 1976; Occurrence of Cl-inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activity. Haemostasis 5: 136
    PubMedGoogle Scholar
  • 18 Kluft C. 1977; a Assay for prekallikrein levels and prekallikrein activation in human plasma using dextran sulphate as a soluble activator. Thrombosis and Haemostasis 38: 220
    PubMedGoogle Scholar
  • 19 Kluft C. 1977; b Properties and origin of Cl-inactivator resistant fibrinolytic activity. Thrombosis and Haemostasis 38: 212
    PubMedGoogle Scholar
  • 20 Kluft C. 1977; C An inventory of plasminogen activators in human plasma. Thrombosis and Haemostasis 38: 134
    PubMedGoogle Scholar
  • 21 Kluft C. 1978; a Determination of prekallikrein in human plasma. Optimal conditions for activating prekallikrein Journal of Laboratory and Clinical Medicine 91: 83
    PubMedGoogle Scholar
  • 22 Kluft C. 1978. b Levels of plasminogen activators in human plasma. New methods to study the intrinsic and extrinsic activators In: Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds.) Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3. Raven Press; New York: p 141
    Google Scholar
  • 23 Kluft C, Brakman P. 1975. The effect of flufenamate on euglobulin fibrinolysis: Involvement of Cl-inactivator. In: Davidson JF, Samama MM, Desnoyers PC. (eds.) Progress in Chemical Fibrinolysis and Thrombolysis. Vol. 1. Raven Press; New York: p 375
    Google Scholar
  • 24 Kluft C, Brakman P, Veldhuyzen-Stolk EC. 1976. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Davidson JF, Samama MM, Desnoyers PC. (eds.) Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 2. Raven Press; New York: p 57
    Google Scholar
  • 25 Kluft C, Jenks RL, Astrup T. 1977; Production of plasminogen activator in factor XII- deficient plasma. Thrombosis Research 10: 759
    CrossrefPubMedGoogle Scholar
  • 26 Macfarlane RG, Pilling J. 1946; Observations on fibrinolysis. Plasminogen, plasmin and antiplasma content of human blood Lancet 2: 562
    PubMedGoogle Scholar
  • 27 Mancini G, Carbonara AO, Heremans JF. 1965; Immunochemical quantitation of antigens by single radial immundiffusion. Immunochemistry 2: 235
    CrossrefPubMedGoogle Scholar
  • 28 Ogston D, Ogston CM, Ratnoff OD, Forbes CD. 1969; Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. Journal of Clinical Investigation 48: 1786
    CrossrefPubMedGoogle Scholar
  • 29 Olesen ES. 1959; a Effect of anionic polyelectrolytes on the fibrinolytic system of guinea-pig serum. Acta Pharmacol Toxicol 16: 38
    PubMedGoogle Scholar
  • 30 Olesen ES. 1959; b Peptone activation of a serum fibrinolytic system. Acta Pharmacol Toxicol 15: 197
    PubMedGoogle Scholar
  • 31 Olesen ES. 1961; A fibrinolytic system in human plasma activated by peptone or acid polysaccharides. Scandinavian Journal of Clinical and Laboratory Investigation 13: 410
    CrossrefPubMedGoogle Scholar
  • 32 Robertson BR, Pandolfi M, Nilsson IM. 1972; ”Fibrinolytic capacity” in healthy volunteers at different ages as studied by standardized venous occlusion of arms and legs. Acta medica Scandinavia 191: 199
    PubMedGoogle Scholar
  • 33 Schreiber AD, Austen KF. 1974; Hageman factor-independent fibrinolytic pathway. Clinical Experimental Immunologie 17: 587
    PubMedGoogle Scholar
  • 34 Trumpi-Kalshoven MM, Kluft C, Jie AF H. 1977; Cl-inactivator as the main inhibitor of high molecular weight human plasma kallikrein. 11th FEBS Meeting Copenhagen Abstract nr A6-6 865
    PubMedGoogle Scholar
  • 35 Ungar G, Mist SH. 1949; Observations on the release of serum fibrinolysin by specific antigen, peptone, and certain polysaccharides. Journal of Experimental Medicine 90: 39
    CrossrefPubMedGoogle Scholar
  • 36 Vogelaar EF, Brummelhuis HG J, Krunen HW. 1974; Contributions to the optimal use of human blood. Ill Large-scale preparation of human Cl-esterase inhibitor concentrate for clinical use Vox Sang 26: 118
    CrossrefPubMedGoogle Scholar